BECTON, DICKINSON AND COMPANY Funds and ETFs Becton, Dickinson and Company
Equities
BDX
US0758871091
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 233.6 USD | -1.51% |
|
-0.06% | -4.20% |
| May. 06 | Barclays Adjusts Price Target on Becton, Dickinson to $312 From $305, Keeps Overweight Rating | MT |
| May. 03 | TD Cowen Adjusts Price Target on Becton, Dickinson and Company to $260 From $271 | MT |
ETFs positioned on Becton, Dickinson and Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.40% | 0 M€ | +12.09% | - | |
| 2.47% | 6 M€ | +16.84% | - | |
| 2.09% | 0 M€ | +5.54% | - | |
| 1.71% | 4,592 M€ | +11.18% | ||
| 0.87% | 9 M€ | -.--% | - | |
| 0.83% | 0 M€ | +8.89% | ||
| 0.81% | 469 M€ | -2.05% | - | |
| 0.81% | 3,859 M€ | +18.82% | - | |
| 0.79% | 2 M€ | +20.44% | - | |
| 0.69% | 5 M€ | -72.95% | - | |
| 0.60% | 5 M€ | -.--% | - | |
| 0.43% | 219 M€ | +17.17% | - | |
| 0.43% | 1,448 M€ | -.--% | - | |
| 0.43% | 0 M€ | +7.71% | ||
| 0.38% | 0 M€ | -.--% | ||
| 0.33% | 0 M€ | +3.31% | - | |
| 0.32% | 0 M€ | +7.60% | ||
| 0.30% | 276 M€ | +11.40% | - | |
| 0.29% | 559 M€ | +14.30% | - | |
| 0.29% | 1,848 M€ | +18.39% | - | |
| 0.27% | 0 M€ | +8.05% | ||
| 0.27% | 0 M€ | +4.95% | - | |
| 0.27% | 414 M€ | +11.14% | - | |
| 0.27% | 1,006 M€ | -.--% | - | |
| 0.26% | 0 M€ | +18.44% | - |
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
233.6
USD
Average target price
278.8
USD
Spread / Average Target
+19.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.20% | 67.51B | |
| -4.66% | 183B | |
| -1.01% | 108B | |
| +2.68% | 50.67B | |
| +9.12% | 44.7B | |
| +2.41% | 40.95B | |
| +4.13% | 26.71B | |
| +3.31% | 26.8B | |
| +12.66% | 24.62B | |
| -0.70% | 24.86B |
- Stock Market
- Equities
- BDX Stock
- Funds and ETFs Becton, Dickinson and Company